Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Terns Pharmaceuticals, Inc. (TERN) · filed Jul 17, 2024

Accession no.
0000947871-24-000627
Filed
Jul 17, 2024, 8:48 PM ET
Trade date
Jul 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions. Open-market sales total $561.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Capital GP VII LLCCIK 0001760648Director, 10% Owner
OrbiMed Genesis GP LLCCIK 0001808744Director, 10% Owner
OrbiMed Asia GP III, L.P.CIK 0001841462Director, 10% Owner
OrbiMed Advisors III LtdCIK 0001841537Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 15, 2024Common StockSSaleDisposed−39,433$10.00−$394,3304,843,421IndirectDuplicate filing
Jul 15, 2024Common StockSSaleDisposed−5,401$10.00−$54,0101,968,480IndirectDuplicate filing
Jul 15, 2024Common StockSSaleDisposed−6,142$10.00−$61,420756,258IndirectDuplicate filing
Jul 16, 2024Common StockSSaleDisposed−4,009$10.00−$40,0904,839,412IndirectDuplicate filing
Jul 16, 2024Common StockSSaleDisposed−556$10.00−$5,5601,967,924IndirectDuplicate filing
Jul 16, 2024Common StockSSaleDisposed−623$10.00−$6,230755,635IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)